Pdt Partners, LLC Kura Oncology, Inc. Transaction History

Pdt Partners, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$12.01 - $19.45 $197,048 - $319,116	-16,407 Reduced 18.6%	71,810 $981,000
Q2 2022 Aug 15, 2022	BUY	$10.71 - $18.33 $1,606 - $2,749	150 Added 0.17%	88,217 $1.62 Million
Q1 2022 May 16, 2022	BUY	$11.78 - $16.98 $789,342 - $1.14 Million	67,007 Added 318.17%	88,067 $1.42 Million
Q4 2021 Feb 14, 2022	BUY	$12.22 - $19.57 $257,353 - $412,144	21,060 New	21,060 $295,000
Q3 2020 Nov 16, 2020	SELL	$16.3 - $30.64 $184,744 - $347,273	-11,334 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$7.95 - $18.81 $342,382 - $810,090	-43,067 Reduced 79.17%	11,334 $185,000
Q1 2020 May 15, 2020	BUY	$6.45 - $14.04 $69,892 - $152,137	10,836 Added 24.87%	54,401 $541,000
Q4 2019 Feb 14, 2020	BUY	$12.97 - $15.94 $216,910 - $266,580	16,724 Added 62.31%	43,565 $599,000
Q3 2019 Nov 14, 2019	BUY	$14.75 - $20.87 $86,154 - $121,901	5,841 Added 27.81%	26,841 $407,000
Q2 2019 Aug 14, 2019	BUY	$14.71 - $19.79 $308,910 - $415,590	21,000 New	21,000 $413,000

185

81.8M

42.1K

34K

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $598M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.